Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Too Much of a Good Thing
      • Turning Face Perception on Its Head
      • Safeguarding a Second Chance at Life
      • A Biological Betrayal
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
        • Earl Stadtman Investigator Frequently Asked Questions
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
The NIH Catalyst: A Publication About NIH Intramural Research

National Institutes of Health • Office of the Director | Volume 31 Issue 2 • March–April 2023

The SIG Beat: Psychedelic Medicine

NEWS FROM AND ABOUT THE SCIENTIFIC INTEREST GROUPS

Psychedelic Medicine Returns to the NIH

Lecture by a SIG in Development

BY NIH CATALYST STAFF

More than 60 NIH researchers representing multiple institutes, disciplines, and generations tuned in on January 24, 2023, for the inaugural meeting of the Psychedelic Science and Medicine Interest Group.

And if their enthusiastic reception was any indication, it appears that the NIH is primed to start anew on research on molecules, receptors, and neural systems that mediate the actions of psychedelic drugs.

Psychedelic drugs, according to the National Institute on Drug Abuse (NIDA), are characterized as classic hallucinogens that can cause users to see images, hear sounds, and feel sensations that seem real but do not exist. Such drugs include the synthetic hallucinogen LSD and natural products such as mescaline (peyote cactus) and psilocybin (“magic mushrooms”).

mushrooms

CREDIT: ARP, WIKIMEDIA COMMONS

Fruit bodies of the hallucinogenic mushroom Psilocybe semilanceata, which produces psilocybin and other psychoactive compounds.

The very notion of studies on psychedelics might conjure up memories of Timothy Leary, leader of the controversial Harvard Psilocybin Project, and even research funded by the NIH in the 1950s and 1960s. The early research environment was marred, however, by a naive and experimenting 1960s youth counterculture, in part instructed by Leary himself to “Turn on, tune in, drop out.”

Universities and the NIH began to question the safety and legitimacy of this line of research. Researchers themselves, by and large, did drop out…of studying psychedelics. The Controlled Substances Act of 1970 classified psilocybin, the main psychoactive constituent of psychedelic mushrooms, as a Schedule I substance—denoted as having no accepted medical use and a high potential for abuse.

Federal funding on psychedelics would remain dry for 50 years, until 2021 when Johns Hopkins University (Baltimore) was awarded a nearly $4 million NIH grant to investigate the potential effects of psilocybin on tobacco addiction. This study had followed a slow but steady resurgence in research with psychedelics in the preceding two decades on major depression, cancer-related existential distress, and substance-use disorders, funded mostly by philanthropy.

Today, researchers are seeing a surge of clinical trials nationwide using psychedelic drugs such as psilocybin and LSD, according to David Goldman, Clinical Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Goldman led the inaugural meeting of this interest group with a talk titled “State of Psychedelics,” in which he discussed the history and nature of psychedelic drugs and summarized their diverse effects, mechanisms, and origins from plants, fungi, and even toads.

He discussed pitfalls in clinical trials with psychedelic drugs, including the importance of concurrent psychotherapy, expectancy, and placebo effects, and the peculiar problem that participants who do not receive the expected drug can react negatively, a phenomenon known as nocebo effect.

The robust change in research funding could be attributed to the success of the use of ketamine to treat depression and suicidal tendencies, according to Carlos Zarate Jr., a world-renowned leader in ketamine research and Chief of the Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health.

Ketamine is a dissociative drug, not a classic hallucinogenic, according to NIDA. Zarate explained that in the 2000-2009 decade, the NIH intramural research program was able to conduct safe and well-designed clinical studies on ketamine and demonstrate its ability to elicit rapid and lasting improvement.

Joking that his opinion was his own and should be subject to editorial review, he speculated that ketamine helped relaunch psychedelic medicine by defining a pathway for other high-risk, high-reward research.

Also aiding in the psychedelic renaissance was the growing recognition of the importance of clinical setting. Goldman additionally mentioned a well-conducted study by researchers at Yale University (New Haven, Connecticut) and the University of New Mexico (Albuquerque, New Mexico) on the use of psilocybin and alcohol-use disorder.

Jessica Laudie, a Postbaccalaureate Fellow in the NIAAA Office of the Clinical Director, originated the idea for the Psychedelic Science and Medicine Interest Group, seeking guidance from Goldman, Nancy Diazgranados, (NIAAA Deputy Clinical Director), and Ann Berger (Chief, Pain and Palliative Care, NIH Clinical Center).

“With a majority, if not all, of psychedelic research occurring outside the NIH, I realized there was a disconnect between the intramural program and psychedelic researchers,” Laudie told The NIH Catalyst. “I wanted to create a space where those currently leading the movement could share their work with those who are interested in learning more, or who may have critical perspectives to offer.”


For more details about this group and instructions for joining its LISTSERV, please visit https://oir.nih.gov/sigs/psychedelic.

This page was last updated on Thursday, March 16, 2023

  • Issue Overview
  • Features
    • Beauty Is in the Eye of the Gecko
    • The NIH Catalyst Celebrates 30 Years
    • Interview with John I. Gallin, M.D.
    • The Faucet of Youth
    • NINR’s New Scientific Director: Sabrina Wong, R.N., Ph.D.
    • Meet 18 New Stadtman Investigators
    • Inclusion of People with Disabilities in Technology Research and Development
    • Our Shared Ancestry in African Genomes Can Be Harnessed to Improve Health For All
    • What We’re Reading
    • COVID-19 Timeline at NIH (January-February 2023)
  • Departments
    • From the Deputy Director for Intramural Research
    • Commentary
    • News Briefs
    • Research Briefs
    • The Training Page
    • News You Can Use: Technology Transfer
    • The SIG Beat: Psychedelic Medicine
    • The SIG Beat: New SIGS
    • Photographic Moment
    • Announcements: Kudos
    • Announcements
  • Issue Contents
  • Download this issue as a PDF

Catalyst menu

  • Current Issue
  • Previous Issues
  • About The NIH Catalyst
  • Contact The NIH Catalyst
  • Share Your Story
  • NIH Abbreviations

Catalyst links

  • Follow The NIH Catalyst

Subscribe Today!

Subscribe to The NIH Catalyst Newsletter and receive email updates.

Subscribe

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search